Low Blood Sugar May Harm the Eyes in People with Diabetes 

Most people with diabetes know that high blood sugar can damage the eyes. But new research suggests that low blood sugar, also called hypoglycemia, may also increase the risk of eye damage. A study by researchers at Johns Hopkins Medicine found that low blood sugar can weaken an important protective layer in the eye called the blood-retinal barrier. This barrier controls the movement of nutrients, fluids, and waste in and out of the retina, the part of the eye responsible for vision. When this barrier breaks down, blood vessels in the retina can leak, leading to damage and possible vision loss. The study, published in Science Translational Medicine, showed that during episodes of low blood sugar, a protein called hypoxia-inducible factor (HIF) builds up in the retina. High levels of HIF can trigger the overgrowth and leakage of blood vessels, which are key features of diabetic retinopathy, a serious complication of diabetes that can cause permanent blindness if not treated. Researchers tested diabetic mice and found that those experiencing low blood sugar had much higher levels of HIF, leading to damage of the blood-retinal barrier. However, when scientists used an experimental drug called 32-134D to block HIF, the damage was reduced. These findings may explain why some patients who tightly control their blood sugar, or who experience frequent ups and downs in glucose levels, sometimes see worsening of diabetic eye disease. Scientists hope that future treatments targeting HIF could help prevent or slow diabetic retinopathy and protect vision in people with diabetes.

Return to top

Stem Cell Therapy Shows New Hope for Stroke Recovery

Stroke is one of the leading causes of disability worldwide. In fact, about one in four adults will experience a stroke during their lifetime. Many survivors are left with lasting problems such as paralysis, difficulty speaking, or trouble walking because brain cells die when blood flow or oxygen supply is cut off. Until now, there has been no treatment that can repair this kind of brain damage. Now, scientists at the University of Zurich have made an exciting breakthrough. In studies on mice, researchers found that transplanting neural stem cells into the damaged brain area could reverse the effects of stroke. These stem cells were created from human cells and have the ability to develop into different types of brain cells. One week after inducing stroke in mice, researchers transplanted the stem cells into the injured brain region. Over the next five weeks, the cells survived and most of them turned into healthy neurons. Even more importantly, these new neurons connected and communicated with existing brain cells. The benefits did not stop there. Scientists also observed new blood vessel growth, reduced inflammation, and improved strength of the blood-brain barrier. The treated mice showed better movement and motor function, proving that the therapy helped restore physical abilities. Although the results are very promising, researchers say more work is needed before this treatment can be used safely in humans. They are currently developing safety systems and less invasive delivery methods. If future clinical trials are successful, stem cell therapy could offer new hope for millions of stroke patients worldwide.

Return to top

Two Common Drugs May Help Treat Fatty Liver Disease 

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as fatty liver disease, is now the most common liver disorder in the world. It affects about one in three adults. The condition happens when too much fat builds up in liver cells, increasing the risk of liver damage and heart disease. Now, researchers at the University of Barcelona have discovered a promising new treatment approach. Their study found that combining two existing medicines, pemafibrate and telmisartan, significantly reduced liver fat and lowered cardiovascular risk in animal models of MASLD. Pemafibrate is a drug used to lower blood fats, while telmisartan is commonly prescribed to treat high blood pressure. Both drugs are already used to reduce heart disease risk. When tested together, they worked better than when used alone. In fact, using half doses of both drugs was as effective as a full dose of either drug by itself. This suggests the combination may provide strong benefits with fewer side effects. The researchers also discovered a new role for a protein called PCK1. Telmisartan helped restore normal levels of this protein in the liver. PCK1 appears to shift how the liver processes nutrients, reducing fat production without raising harmful blood sugar levels. Although the results are encouraging, the research was done in animals, including rats and zebrafish. More studies in humans are needed before this treatment can become widely available. Still, this drug combination offers new hope. Because both medicines are already approved and considered safe, they could potentially provide a faster and more affordable way to treat early-stage fatty liver disease and lower the risk of heart complications.

Return to top

Chlamydia pneumoniae may fuel Alzheimer’s disease 

A common respiratory bacterium, Chlamydia pneumoniae, best known for causing pneumonia and sinus infections, may also contribute to Alzheimer's disease. Researchers at Cedars-Sinai report that the bacterium can persist for years in both the eye and the brain, potentially worsening the neurodegeneration linked to Alzheimer’s. Their findings, published in Nature Communications, suggest that targeting chronic infection and inflammation could open new treatment avenues, including early antibiotic intervention and anti-inflammatory therapies. For the first time, scientists demonstrated that Chlamydia pneumoniae can travel to the retina, the light-sensitive tissue at the back of the eye. There, it triggers immune responses associated with inflammation, nerve cell loss, and cognitive decline. The team analyzed retinal tissue from 104 individuals with normal cognition, mild cognitive impairment, or Alzheimer’s disease, using advanced imaging, genetic testing, and protein studies. Patients with Alzheimer’s showed significantly higher levels of the bacterium in both retinal and brain tissues compared to cognitively normal participants. Higher bacterial levels correlated with more severe brain damage and greater cognitive impairment. Elevated infection levels were particularly common among carriers of the APOE4 variant, a known genetic risk factor for Alzheimer’s. Laboratory studies of human nerve cells and mouse models of Alzheimer’s further supported the link: infection increased inflammation, accelerated nerve cell death, worsened cognitive problems, and stimulated production of amyloid-beta, the protein that accumulates in Alzheimer’s brains. Researchers conclude that retinal infection and chronic inflammation may mirror brain pathology, supporting retinal imaging as a noninvasive method to identify individuals at risk and potentially guide earlier intervention strategies.

Return to top

Antibiotic resistance (AR) has rapidly escalated into a global health emergency. As disease-causing bacteria evolve to survive previously effective treatments, drug-resistant “superbugs” continue to spread. Projections warn that by 2050, these infections could cause more than 10 million deaths annually worldwide. At the University of California, San Diego, Professors Ethan Bier and Justin Meyer from the School of Biological Sciences have developed a novel strategy to eliminate resistance traits from bacterial populations. Their method builds on CRISPR gene-editing technology and borrows principles from gene drives used in insects to curb harmful traits, such as malaria transmission. The team created a second-generation Pro-Active Genetics (Pro-AG) system called pPro-MobV. This innovation expands on earlier work begun in 2019, when Bier’s lab collaborated with Professor Victor Nizet’s team at the School of Medicine to design the original Pro-AG platform. That first system introduced a genetic cassette into bacteria that could copy itself between genomes and disable antibiotic resistance genes. The cassette specifically targets resistance genes carried on plasmids, small circular DNA molecules within bacterial cells. By inserting into plasmids, it disrupts resistance genes, restoring bacterial susceptibility to antibiotics. The updated pPro-MobV system enhances this process through conjugal transfer, a bacterial “mating” mechanism that enables CRISPR components to move from one cell to another. Published in the journal npj Antimicrobials and Resistance, the researchers demonstrated that pPro-MobV spreads through natural mating channels and functions effectively within biofilms, dense microbial communities that protect bacteria from antibiotics and are implicated in most serious infections. Additionally, elements of the system can be delivered by bacteriophages (phage), viruses that infect bacteria and are already being engineered to combat resistance. As a safeguard, the platform includes homology-based deletion, allowing removal of the genetic cassette if needed.

Return to top

HPV vaccine trains T cells to hunt down cancer

Over the past decade, researchers at Northwestern University have uncovered a critical insight: in vaccines, structure matters as much as ingredients. By precisely arranging components at the nanoscale, scientists can dramatically influence immune performance. The team applied this principle to therapeutic vaccines for HPV-driven cancers. They engineered a spherical nucleic acid (SNA) vaccine, a globular DNA-based nanostructure invented by nanotechnology pioneer Chad A. Mirkin and reorganized how a single HPV-targeting peptide was positioned within it. Each vaccine version contained identical ingredients: a lipid core, immune-stimulating DNA, and a fragment of an HPV protein. The only difference was the peptide’s placement, either hidden inside the nanoparticle or displayed on the surface, attached at the N-terminus or C-terminus. The configuration displaying the antigen on the surface via its N-terminus produced the strongest immune response. It generated up to eight times more interferon-gamma from CD8 “killer” T cells and significantly improved tumor cell destruction. In humanized mouse models of HPV-positive cancer, tumor growth slowed and survival improved. In tumor samples from patients with head and neck cancer, cancer cell killing increased two- to threefold. HPV causes most cervical cancers and a rising share of head and neck cancers. While preventive vaccines block infection, they do not treat existing tumors. This therapeutic approach aims to activate powerful CD8 T cells against established cancers. Mirkin calls the strategy “structural nanomedicine” designing medicines from the bottom up with defined architecture rather than using the traditional “blender” mixing approach. The team has applied this platform to melanoma, triple-negative breast, colon, prostate and Merkel cell cancers. Seven SNA-based drugs have entered clinical trials, and SNAs appear in more than 1,000 commercial products. The findings suggest that optimizing nanoscale structure potentially with AI, could transform cancer vaccine design without changing core ingredients.

Return to top